Yong-Chen William Lu, PhD, a fellow in the Surgery Branch of the National Cancer Institute, discusses a CD4 T-cell immunotherapy targeting MAGE-A3 that is showing early clinical responses in patients with metastatic cancer.

In this phase I dose-escalation study, researchers investigated the genetically engineering CD4 T cells, which target the MAGE-A3 protein. Eight patients were treated with various doses of the modified CD4 T-cells, ranging from 10 million to 30 billion cells; 6 patients received the highest dose level of 100 billion cells. 

Three patients (1 with cervical cancer, 1 with esophageal cancer, and 1 with urothelial carcinoma) responded to the therapy, Lu explains, adding these responses are ongoing. Though such T-cell therapies have elicited responses in hematologic malignancies, Lu hopes that, with this study, patients with solid tumors will be able to benefit from the therapy.  

View more from the 2016 AACR Annual Meeting

Videos

Yong-Chen William Lu, PhD, a fellow in the Surgery Branch of the National Cancer Institute, discusses a CD4 T-cell immunotherapy targeting MAGE-A3 that is showing early clinical responses in patients with metastatic cancer.


Yong-Chen William Lu, PhD

Articles

Yong-Chen William Lu on Adoptive T-Cell Therapy in Solid Tumors